Ignite Creation Date:
2024-05-06 @ 3:04 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02193191
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-07
First Post:
2014-07-15
Brief Title:
Escalation of Plerixafor for Mobilization of CD34 Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34 Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to test the safety and efficacy of a drug called Plerixafor Plerixafor is approved by the US FDA for use in increasing blood stem cell counts before collection in cancer patients It is not yet approved for patients with sickle cell disease The investigators want to find out if Plerixafor can be used to increase cell counts in patients with sickle cell disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None